Syncom Formulations to Hold 37th AGM on September 29, 2025 via VC
The resolutions to be passed, including director appointments and remuneration, and changes to MOA/AOA, have a moderate impact on the company's governance and operations.
The announcement is about the AGM and various resolutions to be passed, which is a routine corporate event. Hence, sentiment is neutral.
* Syncom Formulations (India) Limited will hold its 37th Annual General Meeting (AGM) on Monday, September 29, 2025, at 2:00 P.M. (IST) through Video Conferencing (VC)/Other Audio-Visual Means (OAVM). * The Registered Office of the company will be deemed as the venue for the AGM. * The meeting will address several key items, including: * Adoption of Standalone and Consolidated Audited Financial Statements for the year ended March 31, 2025. * Ratification of remuneration payable to M/s M. Goyal & Co., Cost Accountants, for FY 2025-26 (₹50,000 plus applicable taxes). * Confirmation of the appointment of M/s D.K. Jain & Co. as Secretarial Auditors for a 5-year term (2025-26 to 2029-30). * Confirmation of the appointment and remuneration of Shri Ankit Kedarmal Bankda as Executive Chairman and Whole-time Director for a 3-year term from August 9, 2025 (salary up to ₹7,50,000 per month with a 10% annual increment, subject to limits under the Companies Act, 2013). * Approval of increased remuneration for Mr. Rahul Vijay Bankda, Chief Financial Officer, up to ₹50,00,000 p.a. with a 10% annual increment from October 1, 2025. * Alterations to the Articles of Association (AOA) and Memorandum of Association (MOA) of the Company, including new clauses related to power purchase agreements, real estate development, and nutraceuticals. * The company has fixed the closure of Register of Members and Share Transfer Books from 23rd September, 2025 to 29th September, 2025. * Remote e-voting facility will be provided to members, with voting rights proportional to their shares as of the cut-off date, September 22, 2025. * CS Anish Gupta has been appointed as the Scrutinizer for the e-voting process. * Members can address questions in writing to finance@sfil.in at least 7 days before the meeting.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under agm-egm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.